Cost-effectiveness analysis of faricimab and others treatment schemes for diabetic macular edema and age-related macular degeneration

Chronic diseases and aging are rising in Peru, demanding further resources for treatments to both patients and the public health system. These two trends are linked with diseases like diabetic macular edema (DME) and age-related macular degeneration (AMD). DME is related to diabetes, a disease that affects 1.3 million adults aged 20 to 79, with around 40% remaining undiagnosed. On the other hand, wet AMD leads vision loss, accounting for 12% of cases of blindness in Peru. Within this framework, this research aims to determine which of the treatment schemes (faricimab, bevacizumab, aflibercept and ranibizumab) for DME and AMD is most cost effective in Peru (EsSalud).